Serosurvey and Cellular Immune Status of HTLV-1/2 and HIV Co-infections in Bauchi State, Nigeria

Skrócona strona pozycji
dc.contributor.authorBabayo, Adamu
dc.contributor.authorAzeez Akande, Oyebanji
dc.contributor.authorSabo, Yusuf Mohammed
dc.contributor.authorAbdullahi, Idris Nasir
dc.contributor.authorDangana, Amos
dc.date.accessioned2020-01-21T09:33:55Z
dc.date.available2020-01-21T09:33:55Z
dc.date.issued2019
dc.description.abstractIntroduction. Human T-cell lymphotropic virus types 1 and 2 (HTLV-1 & 2) are frequent co-pathogens among immunosuppressed individuals, particularly HIV/AIDS infected persons. Dual infected persons usually present with false normal or high CD4+ T cells count as a result of the ability of HTLV to induce clonal proliferation of CD4+ T lymphocytes. There is paucity of information on this clinical entity in Nigeria. Aim. This study aimed to determine the seroprevalence of HTLV-1/2 and associated cellular immune response among antiretroviral naďve and experienced HIV infected persons at Bauchi State, Nigeria. Material and methods. One hundred and eighty two (182) HIV seropositive patients’ blood samples were analyzed for anti HTLV-1/2 IgM and IgG antibodies using ELISA while CD4+ T cells were counted using Flow cytometry technique. Socio-demographic data of the subjects and clinical history were obtained via questionnaire and medical records, respectively. Results. The seroprevalence of anti-HTLV-1/2 was 14%. This comprised 76 (41.8%) males and 106 (58.2%) females. Six (3%) were seropositive for both ant-HTLV -1&2 IgM and IgG. Of the total positive for anti-HTLV-1/2, 20 (25%) ART-naďve and 6(5.9%) ART-experience subjects. Whole blood CD4+ T cell count was significantly high in HTLV-1/-2 IgG/IgM seropositive subjects compared to their HTLV-1/-2 negative counterpart. Conclusion. All subjects (100%) who were HTLV-1/-2/HIV co-infected had normal to higher CD4+ T cell counts. It is suggested to be very careful in using only CD4+ counts to monitor HIV progression or as indicators for ART.pl_PL.UTF-8
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 17, z. 4 (2019), s. 289–294pl_PL.UTF-8
dc.identifier.doi10.15584/ejcem.2019.4.1
dc.identifier.eissn2544-1361
dc.identifier.issn2544-2406
dc.identifier.urihttp://repozytorium.ur.edu.pl/handle/item/5175
dc.language.isoengpl_PL.UTF-8
dc.publisherWydawnictwo Uniwersytetu Rzeszowskiegopl_PL.UTF-8
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHTLVpl_PL.UTF-8
dc.subjectcellular Immunitypl_PL.UTF-8
dc.subjectHIV co-infectionspl_PL.UTF-8
dc.subjectantiretroviral therapypl_PL.UTF-8
dc.titleSerosurvey and Cellular Immune Status of HTLV-1/2 and HIV Co-infections in Bauchi State, Nigeriapl_PL.UTF-8
dc.typearticlepl_PL.UTF-8
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
1 babayo-serosurvey.pdf
Rozmiar:
313.76 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.22 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.17, z. 4 (2019)